Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × cabozantinib × Thoracic × Clear all

Phase

Phase 2 10 Phase 1 5 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 8 Plasma cell 2 Gastrointestinal 2 Thoracic 1 Sarcoma 1 NET 1 Endocrine 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1

Interventions

pembrolizumab 109 Carboplatin 101 Pemetrexed 65 Cisplatin 64 Nivolumab 59 Paclitaxel 53 Docetaxel 52 Erlotinib Hydrochloride 38 Radiotherapy 36 Gemcitabine 31 Etoposide 29 osimertinib 27 atezolizumab 25 Cetuximab 25 Ipilimumab 23 Bevacizumab 23 Radiosurgery 19 durvalumab 18 Drug Therapy 17 Cyclophosphamide 17 130-nm albumin-bound paclitaxel 15 Taxes 14 avelumab 13 Irinotecan 13 Albumin-Bound Paclitaxel 13 Injections 12 Gefitinib 11 Radiation 10 Topotecan 9 fludarabine 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04151563 2023-12-19

CheckMate 79X

Bristol-Myers Squibb

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡